Pre-primary and Primary Prophylaxis of Variceal Hemorrhage

[1]  T. Walther,et al.  Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. , 2013, Gastroenterology.

[2]  D. Schuppan,et al.  Evolving therapies for liver fibrosis. , 2013, The Journal of clinical investigation.

[3]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[4]  J. Bosch.  Carvedilol: the β-blocker of choice for portal hypertension? , 2013, Gut.

[5]  R. Groszmann,et al.  Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage. , 2013, Annals of hepatology.

[6]  L. Kramer,et al.  Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol , 2012, Gut.

[7]  T. Sauerbruch,et al.  HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.

[8]  F. Lammert,et al.  Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats , 2012, Laboratory Investigation.

[9]  A. Krag,et al.  Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. , 2012, The Cochrane database of systematic reviews.

[10]  J. Daurès,et al.  Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. , 2012, Annals of hepatology.

[11]  D. Rockey,et al.  Complications of cirrhosis , 2012, Current Opinion in Gastroenterology.

[12]  J. Bosch,et al.  Randomised clinical trial: the safety and efficacy of long‐acting octreotide in patients with portal hypertension , 2012, Alimentary pharmacology & therapeutics.

[13]  J. Bosch,et al.  Non invasive evaluation of portal hypertension using transient elastography. , 2012, Journal of hepatology.

[14]  A. Gerbes,et al.  Spontaneous bacterial peritonitis: recent guidelines and beyond , 2011, Gut.

[15]  J. West,et al.  Reductions in 28-Day Mortality Following Hospital Admission for Upper Gastrointestinal Hemorrhage , 2011, Gastroenterology.

[16]  B. Sharma,et al.  Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial. , 2011, Journal of hepatology.

[17]  D. Brenner,et al.  Anti-fibrogenic strategies and the regression of fibrosis. , 2011, Best practice & research. Clinical gastroenterology.

[18]  C. Hellerbrand,et al.  Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction , 2011, Gut.

[19]  H. Nischalke,et al.  Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis , 2011, Laboratory Investigation.

[20]  F. Lammert,et al.  Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.

[21]  A. Gerbes,et al.  Amiloride reduces portal hypertension in rat liver cirrhosis , 2010, Gut.

[22]  R. Bataller,et al.  Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats , 2010, Hepatology.

[23]  P. Jares,et al.  Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans , 2010, Hepatology.

[24]  F. Nevens,et al.  Role of β3‐adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis , 2009, Hepatology.

[25]  J. Iredale,et al.  Reversibility of liver fibrosis. , 2009, Annals of hepatology.

[26]  D. Schuppan,et al.  Rationale and targets for antifibrotic therapies. , 2009, Gastroenterologie clinique et biologique.

[27]  T. Sauerbruch,et al.  Coexisting Gastric Varices Should Not Preclude Prophylactic Ligation of Large Esophageal Varices in Cirrhosis , 2009, Digestion.

[28]  P. Hayes,et al.  Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed , 2009, Hepatology.

[29]  F. Tacke,et al.  Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. , 2009, Gastroenterology.

[30]  T. Sauerbruch,et al.  Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis , 2009, British journal of pharmacology.

[31]  J. Bosch,et al.  Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. , 2009, Gastroenterology.

[32]  S. Raptis,et al.  Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis , 2009, Alimentary pharmacology & therapeutics.

[33]  M. Mejías,et al.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.

[34]  R. Bataller,et al.  Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[35]  S. Ishihara,et al.  Does gastroesophageal reflux have an influence on bleeding from esophageal varices? , 2008, Journal of Gastroenterology.

[36]  T. Sauerbruch,et al.  Irbesartan Plus Low-Dose Propranolol Versus Low-Dose Propranolol Alone in Cirrhosis: A Placebo-Controlled, Double-Blind Study , 2008, The American Journal of Gastroenterology.

[37]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[38]  T. Sauerbruch,et al.  Mechanisms of extrahepatic vasodilation in portal hypertension , 2008, Gut.

[39]  T. Sauerbruch,et al.  Treatment of bile duct‐ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[40]  F. Lammert,et al.  Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats , 2007, Hepatology.

[41]  D. Thabut,et al.  High‐density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats , 2007, Hepatology.

[42]  P. Carmeliet,et al.  Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats , 2007, Hepatology.

[43]  J. Vorobioff.  Hepatic venous pressure in practice: how, when, and why. , 2007, Journal of clinical gastroenterology.

[44]  Yosuke Osawa,et al.  TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.

[45]  M. Mejías,et al.  Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats , 2007, Hepatology.

[46]  A. Burroughs,et al.  A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[47]  F. Nevens,et al.  Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase , 2007, Hepatology.

[48]  F. Brunello,et al.  AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. , 2007, Journal of hepatology.

[49]  J. Bosch,et al.  Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. , 2007, Journal of hepatology.

[50]  N. Chalasani,et al.  Cost‐effectiveness analysis of variceal ligation vs. beta‐blockers for primary prevention of variceal bleeding , 2007, Hepatology.

[51]  T. Fukui,et al.  Probiotics in the prevention of traveler's diarrhea: meta-analysis. , 2007, Journal of clinical gastroenterology.

[52]  T. Sauerbruch,et al.  Vascular dysfunction in human and rat cirrhosis: Role of receptor‐desensitizing and calcium‐sensitizing proteins , 2007, Hepatology.

[53]  F. Nevens,et al.  Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. , 2007, Gastroenterology.

[54]  R. Schwabe,et al.  TLR4 enhances TGF-beta signaling and hepatic fibrosis. , 2007, Nature medicine.

[55]  S. Heffelfinger,et al.  Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. , 2006, Anti-cancer agents in medicinal chemistry.

[56]  Christopher J. Parsons,et al.  LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[57]  K. Jakobs,et al.  Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. , 2006, Gastroenterology.

[58]  T. Sauerbruch,et al.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.

[59]  T. Sauerbruch,et al.  Circadian rhythm of fasting and postprandial portal blood flow in cirrhosis , 2006, Scandinavian journal of gastroenterology.

[60]  Ramon Planas,et al.  Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. , 2005, The New England journal of medicine.

[61]  D. Brenner,et al.  Liver fibrogenesis: a new role for the renin-angiotensin system. , 2005, Antioxidants & redox signaling.

[62]  J. Rodés,et al.  Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. , 2005, Journal of hepatology.

[63]  R. Franchis,et al.  Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. , 2005, Journal of hepatology.

[64]  T. Sauerbruch,et al.  Vascular, hemodynamic and renal effects of low‐dose losartan in rats with secondary biliary cirrhosis , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[65]  Christopher J. Parsons,et al.  Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct–ligated rats , 2005, Hepatology.

[66]  B. Sharma,et al.  Endoscopic Variceal Ligation plus Propranolol versus Endoscopic Variceal Ligation Alone in Primary Prophylaxis of Variceal Bleeding , 2005, The American Journal of Gastroenterology.

[67]  A. Burroughs,et al.  Infection, coagulation, and variceal bleeding in cirrhosis , 2005, Gut.

[68]  R. Wiest,et al.  Bacterial translocation (BT) in cirrhosis , 2005, Hepatology.

[69]  T. Sauerbruch,et al.  Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis , 1986, Klinische Wochenschrift.

[70]  M. JuanJorgeManríquez,et al.  [Critical appraisal: band ligation and propranolol are equally effective for primary prevention of variceal bleeding]. , 2004 .

[71]  Shou-Dong Lee,et al.  Acute Administration of Carvedilol is More Effective than Propranolol Plus Isosorbide-5-Mononitrate in the Reduction of Portal Pressure in Patients with Viral Cirrhosis , 2004, American Journal of Gastroenterology.

[72]  P. Angeli,et al.  A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. , 2004, Gastroenterology.

[73]  G. Lazaraki,et al.  Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. , 2004, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[74]  C. Hellerbrand,et al.  Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis , 2004, Hepatology.

[75]  J. Dixon,et al.  Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss , 2004, Hepatology.

[76]  L. Rallidis,et al.  Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. , 2004, Atherosclerosis.

[77]  A. Alberti,et al.  Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications , 2004, Gut.

[78]  A. Czaja,et al.  Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. , 2004, Journal of hepatology.

[79]  J. Rodés,et al.  Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. , 2004, Gastroenterology.

[80]  J. Rodés,et al.  Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. , 2004, Gastroenterology.

[81]  B. Hemstreet,et al.  Evaluation of Carvedilol for the Treatment of Portal Hypertension , 2004, Pharmacotherapy.

[82]  S. Gurel,et al.  Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[83]  T. Sauerbruch,et al.  Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats , 2003, European journal of clinical investigation.

[84]  R. Schwabe,et al.  NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. , 2003, The Journal of clinical investigation.

[85]  T. Sauerbruch,et al.  Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis , 2003, Alimentary pharmacology & therapeutics.

[86]  H. Yoshiji,et al.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis , 2003, Gut.

[87]  J. Calleja,et al.  Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: A double‐blind RCT , 2003, Hepatology.

[88]  R. Terg,et al.  Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study , 2003, Hepatology.

[89]  D. Chappard,et al.  Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. , 2002, Journal of hepatology.

[90]  J. Bosch,et al.  Randomized comparison of long‐term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis , 2002, Hepatology.

[91]  R. de Franchis,et al.  Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. , 2002, Journal of hepatology.

[92]  Mei‐Hsiu Chen,et al.  Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. , 2002, Gastroenterology.

[93]  V. Desmet,et al.  In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats , 2002, Gut.

[94]  M. Arthur,et al.  Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. , 2002, Gastroenterology.

[95]  P. Hayes,et al.  Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. , 1999, Gastroenterology.

[96]  R. Groszmann,et al.  Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment? , 2001, Hepatology.

[97]  D. Brenner,et al.  Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. , 2001, Journal of hepatology.

[98]  J. Calleja,et al.  Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. , 2001, Gastroenterology.

[99]  T. Sauerbruch,et al.  Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. , 2001, Gastroenterology.

[100]  J. García‐Pagán,et al.  Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis☆☆☆ , 2001 .

[101]  N. Chalasani,et al.  A meta‐analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding , 2001, Hepatology.

[102]  J. García‐Pagán,et al.  Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. , 2001, Gastroenterology.

[103]  D. Valla,et al.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. , 2001, The New England journal of medicine.

[104]  A. Gatta,et al.  The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis , 2000, Hepatology.

[105]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[106]  P. Pagano.  Beyond the Endothelium , 2000 .

[107]  R. Bataller,et al.  Angiotensin II induces contraction and proliferation of human hepatic stellate cells. , 2000, Gastroenterology.

[108]  P. Amodio,et al.  Long‐term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis , 2000, Hepatology.

[109]  J. Bosch,et al.  Complications of cirrhosis. I. Portal hypertension. , 2000, Journal of hepatology.

[110]  Rosa Gilabert,et al.  Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus–related cirrhosis , 1999, Hepatology.

[111]  R. Groszmann,et al.  Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. , 1999, The Journal of clinical investigation.

[112]  C. Klein,et al.  Effect of losartan, an Angiotensin II receptor antagonist, on portal pressure in cirrhosis , 1999, Hepatology.

[113]  A. Burroughs,et al.  Bacterial infection in the pathogenesis of variceal bleeding , 1999, The Lancet.

[114]  C. Sabin,et al.  Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage , 1998, Hepatology.

[115]  E. Lesaffre,et al.  Variceal pressure is a factor predicting the risk of a first variceal bleeding: A prospective cohort study in cirrhotic patients , 1998, Hepatology.

[116]  L. Capocaccia,et al.  Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis. , 1997, Gastroenterology.

[117]  Houston Mc,et al.  Clinical implications of the white nipple sign and its role in the diagnosis of esophageal variceal hemorrhage , 1996 .

[118]  S. D. Lee,et al.  Clinical implications of the white nipple sign and its role in the diagnosis of esophageal variceal hemorrhage. , 1996, The American journal of gastroenterology.

[119]  G. D’Amico,et al.  The treatment of portal hypertension: A meta‐analytic review , 1995, Hepatology.

[120]  P. Hayes,et al.  The acute and chronic effects of isosorbide-5-mononitrate on portal haemodynamics in cirrhosis. , 1994, Journal of hepatology.

[121]  T. Sauerbruch,et al.  Prophylaxis of first variceal bleeding. , 1992, Bailliere's clinical gastroenterology.

[122]  R. Franchis,et al.  Why do varices bleed? , 1992, Gastroenterology clinics of North America.

[123]  T. Poynard,et al.  Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. , 1991, The New England journal of medicine.

[124]  T. Sauerbruch,et al.  Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. , 1991, Gastroenterology.

[125]  L. Howes,et al.  Plasma noradrenaline in cirrhosis: a study of kinetics and temporal relationship to ascites formation , 1991, European journal of clinical investigation.

[126]  R. Groszmann,et al.  Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. , 1991, The Journal of clinical investigation.

[127]  Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. A randomized, single-blind, multicenter clinical trial. , 1991, The New England journal of medicine.

[128]  M. Navasa,et al.  Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. , 1990, Journal of hepatology.

[129]  J. Bruix,et al.  Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. , 1989, Gastroenterology.

[130]  T. Sauerbruch,et al.  Pressure of intraoesophageal varices assessed by fine needle puncture: its relation to endoscopic signs and severity of liver disease in patients with cirrhosis. , 1989, Gut.

[131]  T. Sauerbruch,et al.  Risk indicators of variceal bleeding. , 1988, Zeitschrift fur Gastroenterologie.

[132]  T. Sauerbruch,et al.  Prophylactic sclerotherapy before the first episode of variceal hemorrhage in patients with cirrhosis. , 1988, The New England journal of medicine.

[133]  P. Arcidiacono,et al.  Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study , 1988 .

[134]  E. Ancona,et al.  Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. , 1988, The New England journal of medicine.

[135]  G. Stiegmann,et al.  A new endoscopic elastic band ligating device. , 1986, Gastrointestinal endoscopy.

[136]  H. Conn.  Why do varices bleed? Rational therapy based on objective observations. , 2009, Acta medica Scandinavica. Supplementum.

[137]  G. Johnston,et al.  Oesophageal mucosal changes in patients with varices. , 1983, Gut.

[138]  J. Benhamou,et al.  The Effect of Propranolol on Portal Hypertension in Patients with Cirrhosis: A Hemodynamic Study , 2007, Hepatology.

[139]  S. Kitano,et al.  Prediction of variceal hemorrhage by esophageal endoscopy. , 1981, Gastrointestinal endoscopy.

[140]  J. Benhamou,et al.  PROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION? , 1980, The Lancet.

[141]  J. Benhamou,et al.  Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. , 1980, Gastroenterology.

[142]  J. Villeneuve,et al.  Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. , 1975, Gastroenterology.

[143]  Klipstein Fa,et al.  Letter: Sprue again. , 1975 .

[144]  G. Ramsby,et al.  PROPHYLACTIC PORTACAVAL ANASTOMOSIS: A Tale of Two Studies , 1972 .

[145]  G. Ramsby,et al.  Prophylactic portacaval anastomosis. , 1972, Medicine.

[146]  T. Chalmers,et al.  A controlled study of the prophylactic portacaval shunt. A final report. , 1969, Annals of Internal Medicine.

[147]  E. Perrin,et al.  A clinical investigation of the portacaval shunt. II. Survival analysis of the prophylactic operation. , 1968, American journal of surgery.

[148]  W. Lierse,et al.  [The angiomuscular dilation closing of the terminal esophagus]. , 1968, Langenbecks Archiv fur Chirurgie.

[149]  H. Conn,et al.  PROPHYLACTIC PORTACAVAL ANASTOMOSIS IN CIRRHOTIC PATIENTS WITH ESOPHAGEAL VARICES: A PROGRESS REPORT OF A CONTINUING STUDY. , 1965, The New England journal of medicine.

[150]  H. Liebowitz.  Pathogenesis of esophageal varix rupture. , 1961, JAMA.

[151]  P. Frenckner,et al.  New Surgical Treatment of Varicous Veins of the Oesophagus , 1939 .